325.6000 3.30 (1.02%)
NSE Oct 01, 2026 15:31 PM
Volume: 2.4M
 

325.60
1.02%
Dynamic Levels
Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...
Marksans Pharma Ltd. has an average target of 362.00 from 1 broker.
More from Marksans Pharma Ltd.
Recommended